组蛋白去乙酰化酶抑制剂治疗多发性骨髓瘤的最新进展

• 作者: 徐莉 郑焱华 陈协群 高广勋
• 来源期刊: 临床血液学杂志
• 学科: 医学
• 关键词: 多发性骨髓瘤 组蛋白去乙酰化酶抑制剂
• 年，卷（期）: 2018,（5）
• 所属期刊栏目: 综述
• 页码范围: 402-406
• 页数: 5页
• 分类号: R733.3
• 语种: 中文
• DOI: 10.13201/j.issn.1004-2806.2018.05.019

摘要

Multiple myeloma (MM) is an incurable hematological malignancy characterized by clonal proliferation of plasma cclls within the bone marrow,resulting in anemia,osteolytic lesions,hypercalcemia,monoclonal immunoglobulin in the blood and/or urine, infection and renal impairment. Histone acetyltransferases and histone deacetylases (HDACs) are counteracting epigenetic enzymes regulating the status of protein acetylation thereby modulating gene transcription. Dysfunction of protein acetylation caused by aberrant expression of HDACs plays a critical role in tumor initiation and progression,thus making HDACs potential targets for cancer treatment. Specifically,combination treatment with HDACi (HDAC inhibitor) and proteasome inhibitors (bortezomib, carfilzomib) or immunomodulatory drugs (thalidomide, lenalidomide) shows synergistic anti-MM activity in both fundamental research and clinical trials. In this review, we summarize the recent research progress of HDACi in MM treatment and their mechanisms of anti-MM effect.